PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Key buying criteria PART 06: AMD: Overview • Understanding the disease • Stages of AMD • Etiology • Signs and symptoms • Diagnosis • Management PART 07: Pipeline portfolio PART 08: Market landscape • Market overview PART 09: Market analysis of major drugs • Lucentis • Eylea • Avastin • Five forces analysis PART 10: Market segmentation by type • Global wet AMD market • Market overview • Global dry AMD market • Market overview PART 11: Market segmentation by ROA • IV • Intravitreal PART 12: Geographical segmentation • AMD market in Americas • AMD market in EMEA • AMD market in APAC PART 13: Market drivers • Increase in aging population • Increasing reimbursement benefits for AMD drugs • Increase in diagnosis rate • High patient and physician satisfaction PART 14: Impact of drivers PART 15: Market challenges • Gap in patient demand vs. ophthalmology expert supply • Increasing use of off-label drugs • Availability of alternative therapies PART 16: Impact of drivers and challenges PART 17: Market trends • Novel treatment approaches for developing AMD drugs • Increased research grants, initiatives, and programs • Use of combination therapies PART 18: Vendor landscape • Competitive scenario • Other prominent vendors PART 19: Key vendor analysis • Bayer HealthCare • F. Hoffmann-La Roche • Novartis • Regeneron Pharmaceuticals PART 20: Appendix • List of abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Leading drugs for AMD Exhibit 03: Novel opportunities for AMD market: Entry of squalamine Exhibit 04: Global AMD market snapshot Exhibit 05: Key buying criteria for AMD drugs Exhibit 06: Key buying criteria for global AMD market 2015 Exhibit 07: Impact of key customer segments on global AMD market 2015 Exhibit 08: Stages of AMD Exhibit 09: Risk factors for AMD Exhibit 10: Diagnosis of AMD Exhibit 11: Product portfolio of current AMD therapies Exhibit 12: Share of pipeline molecules in global AMD market Exhibit 13: Prevalence of AMD 2000 and 2050 (millions) Exhibit 14: Global AMD market snapshot: Developed and emerging markets 2015 Exhibit 15: Factors influencing the global AMD market 2015 Exhibit 16: Global AMD market 2015-2020 ($ billions) Exhibit 17: Impact of drivers and challenges of global AMD market Exhibit 18: Opportunity analysis of global AMD market by type Exhibit 19: Timeline of key regulatory approvals of Lucentis Exhibit 20: YoY growth and revenue generated from sales of Lucentis 2013-2015 ($ billions) Exhibit 21: Timeline of key regulatory approvals and filings of Eylea Exhibit 22: YoY revenue and growth rate of Eylea 2012-2015 ($ billions) Exhibit 23: Five forces analysis Exhibit 24: Global AMD market: Segmentation by type 2015-2020 Exhibit 25: Global AMD market segmentation: Growth cycle analysis Exhibit 26: Competitive landscape of wet AMD drugs Exhibit 27: Global wet AMD market 2015-2020 ($ billions) Exhibit 28: Opportunity analysis of global dry AMD market Exhibit 29: Global dry AMD market 2015-2020 ($ millions) Exhibit 30: Segmentation of global AMD market by ROA 2015 Exhibit 31: Global AMD market: Geographical outlook (2015-2020) Exhibit 32: Global AMD market: Geography outlook 2015 Exhibit 33: Revenue/growth outlook in different countries/regions 2015 Exhibit 34: Global AMD market segmentation by region: Market growth lifecycle analysis 2015 Exhibit 35: AMD market revenue by geography 2015-2020 ($ billions) Exhibit 36: Opportunity analysis of AMD market in Americas Exhibit 37: AMD market in Americas 2015-2020 ($ billions) Exhibit 38: Opportunity analysis of AMD market in EMEA Exhibit 39: AMD market in EMEA 2015-2020 ($ billions) Exhibit 40: Opportunity analysis of AMD market in APAC Exhibit 41: Prevalence rates of AMD in APAC countries 2015 Exhibit 42: AMD market in APAC 2015-2020 ($ billions) Exhibit 43: Percentage of Americans with vision loss Exhibit 44: Distribution of population aged 60 years and over (millions) Exhibit 45: Impact of drivers Exhibit 46: Impact of drivers and challenges Exhibit 47: Geographical presence of key vendors Exhibit 48: Company portfolio analysis in global AMD market 2016-2020 Exhibit 49: Bayer HealthCare: Profile Exhibit 50: Bayer HealthCare: Metrics analysis Exhibit 51: Bayer HealthCare: Growth strategy matrix Exhibit 52: Bayer HealthCare: Opportunity assessment Exhibit 53: F. Hoffmann-La Roche: Profile Exhibit 54: F. Hoffmann-La Roche: Metrics analysis Exhibit 55: F. Hoffmann-La Roche: Growth strategy matrix Exhibit 56: F. Hoffmann-La Roche: Opportunity assessment Exhibit 57: Novartis: Specialty ophthalmic segmentation by revenue 2015 Exhibit 58: Novartis: Profile Exhibit 59: Novartis: Metrics analysis Exhibit 60: Novartis: Growth strategy matrix Exhibit 61: Novartis: Opportunity assessment Exhibit 62: Regeneron Pharmaceuticals: Profile Exhibit 63: Regeneron Pharmaceuticals: Metrics analysis Exhibit 64: Regeneron Pharmaceuticals: Growth strategy matrix Exhibit 65: Regeneron Pharmaceuticals: Growth opportunity assessment

Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Adverum Biotechnologies, Bausch + Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior , QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen Pharmaceuticals, and Sanwa Kagaku Kenkyusho.